- Home
- DNMX vs AVTX Comparison
DNMX vs AVTX Comparison
Compare DNMX & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$14.26
Company Overview
Basic Information| Metric | DNMX | AVTX |
|---|---|---|
| Founded | 2025 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.4M | 248.3M |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DNMX | AVTX |
|---|---|---|
| Price | $9.95 | $14.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 77.0K | ★ 387.9K |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.87 | $3.39 |
| 52 Week High | $9.99 | $20.72 |
Technical Indicators
Market Signals| Indicator | DNMX | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.55 | 43.00 |
| Support Level | $9.95 | $13.50 |
| Resistance Level | $9.99 | $14.81 |
| Average True Range (ATR) | 0.01 | 1.12 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 50.00 | 32.45 |
Price Performance
Historical Comparison DNMX
AVTX
About DNMX Dynamix Corporation III Class A Ordinary Shares
Dynamix Corp III is a a blank check company incorporated as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).